AstraZeneca commits USD15B to China expansion through 2030 as Starmer visits Beijing

CHINA—Global pharmaceutical leader AstraZeneca has announced plans to invest USD 15 billion to expand its research and manufacturing capabilities in China by 2030.

The move marks one of the company’s largest single-country investments and underscores China’s growing importance as a hub for pharmaceutical innovation and production.

This extensive investment will strengthen AstraZeneca’s discovery, development, and manufacturing capacity in cutting-edge areas such as cell therapy and radioconjugates.

These advanced technologies are critical to the company’s ongoing efforts to accelerate treatments across oncology, haematology, and autoimmune diseases.

Strengthening local manufacturing footprint

The UK-Swedish pharmaceutical giant intends to channel a major portion of the funding into expanding its local production network.

The investment will enhance AstraZeneca’s existing manufacturing sites in Wuxi, Beijing, Qingdao, and Taizhou, which already serve patients in China and across 70 international markets.

At the same time, the company plans to construct new state-of-the-art facilities across the country.

This broad infrastructure upgrade reflects AstraZeneca’s commitment to bringing high-quality medicines closer to key markets and to advancing the local life sciences ecosystem.

Expanding research and innovation capacity

Beyond manufacturing improvements, the company’s pledge includes a significant boost to its “substantial” R&D network in China.

AstraZeneca currently operates major research centres in Beijing and Shanghai, where its teams focus on innovation in early-stage drug development.

The expanded network will reinforce these centres and promote deeper scientific collaborations with Chinese research institutions and biotech partners.

Timely announcement amidst strengthening UK-China relations

AstraZeneca’s decision coincides with UK Prime Minister Keir Starmer’s three-day visit to Beijing aimed at rebuilding trade and economic ties between the two nations.

In a statement issued on 29 January, Starmer welcomed the investment, praising it as proof of British industry’s global competitiveness.

He noted that the expansion of AstraZeneca’s Chinese operations would “help the British manufacturer continue to grow,” particularly as concerns mount over the UK’s ability to retain its position as a global life sciences hub.

Supporting China’s “Healthy China2030” Vision

The investment also aligns with Chinese President Xi Jinping’s “Healthy China 2030” strategy—the country’s first long-term national health plan since its founding in 1949.

The policy emphasizes improving healthcare quality, advancing disease prevention, and strengthening access to medical innovation.

AstraZeneca’s expansion is expected to complement these national goals by fostering technology transfer, local employment, and cross-border collaboration in healthcare.

China’s rapidly expanding pharmaceutical influence

In recent years, China has emerged as a major force in global pharmaceutical research and development.

Regulatory reforms, better intellectual property frameworks, and supportive government policies have all contributed to this momentum.

According to a GlobalData report, Chinese companies now account for about 20 percent of all drugs in development worldwide—a figure that continues to grow each year.

This shift has also encouraged local biopharma firms to pivot from traditional generics toward more innovative products, including biologics and precision therapies.

Global pharmaceutical players, recognizing this change, have increasingly partnered with Chinese biotech firms to access novel treatments and diversify their pipelines.

AstraZeneca’s ongoing strategic partnership in China

AstraZeneca has been at the forefront of this cooperation, striking multiple high-value licensing agreements with regional companies.

In June 2025, the company finalized a landmark USD 5.2 billion deal with CSPC, signaling its long-term confidence in the Chinese market.

Analysts expect oncology-focused partnerships like this to remain a key growth driver for China’s pharmaceutical sector through 2026.